Assembling and investigating 201Tl radiolabelled texaphyrin nanoparticles targeted to prostate cancer cells for Auger electron radiotherapy
组装和研究针对前列腺癌细胞的 201Tl 放射性标记泰克萨菲林纳米颗粒用于俄歇电子放射治疗
基本信息
- 批准号:NE/T014407/1
- 负责人:
- 金额:$ 1.23万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2020
- 资助国家:英国
- 起止时间:2020 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
"MRC : Katarzyna Osytek : MR/N013700/1"Targeted radionuclide therapy is an emerging and very promising strategy for cancer treatment, as evidenced by the proven clinical success in treating neuroendocrine tumours with 177Lu-DOTATATE and more recently, metastatic prostate cancer with 177Lu-PSMA-617 and 225Ac-PSMA-617. However, beta-particles emitted by 177Lu have disadvantages, particularly their long range (several millimeters) which results in irradiation and toxicity to non-targeted normal cells, as well as their very low LET (0.1-1 keV/um), which limits their cytotoxic potency. Alpha-particle emitters such as 225Ac have a much shorter range of 50-100 um and higher LET (50-230 keV/um) which makes them very potent and selective for killing cancer cells. But a major limitation to alpha-particle radiotherapy is that the radionuclides decay to radioactive daughter products, which can redistribute to normal tissues and cause toxicity. AEs are analogous to alpha-particles in that they have a very short range (<1um) and high LET (4-26 keV/um) and are potent for killing cancer cells, but importantly, AE-emitting radionuclides decay to a stable daughter product. 201Tl is one of the most attractive AE emitters for cancer therapy due to the high abundance of AEs emitted per decay. I will address the challenge of specifically delivering 201Tl into cancer cells in my research proposal at the University of Toronto by exploring a new strategy to deliver this radionuclide using targeted texaphyrin nanoparticles that complex 201Tl.
“MRC:Katarzyna Osytek:MR/N013700/1”靶向放射性核素疗法是一种新兴的非常有前景的癌症治疗策略,177Lu-DOTATE治疗神经内分泌肿瘤以及最近用177Lu-PSMA-617和225Ac-PSMA-617治疗转移性前列腺癌的临床成功证明了这一点。然而,177Lu发射的β粒子也有缺点,特别是它们的射程很长(几毫米),导致对非靶向正常细胞的照射和毒性,以及非常低的LET(0.1-1kev/um),这限制了它们的细胞毒作用。像225Ac这样的阿尔法粒子发射器的射程要短得多,范围在50-100微米,而LET(50-230电子伏安/微米)更高,这使得它们对杀死癌细胞非常有效和有选择性。但阿尔法粒子放射治疗的一个主要限制是放射性核素会衰变成放射性的子产物,可能会重新分布到正常组织并造成毒性。俄歇电子能谱与阿尔法粒子相似,因为它们的射程很短(~lt;1um),LET很高(4-26kev/um),对杀死癌细胞是有效的,但重要的是,发射出的AE放射性核素会衰变成稳定的子产物。201Tl是癌症治疗中最具吸引力的AE发射体之一,因为每次衰变都会释放出高丰度的AEs。在我在多伦多大学的研究提案中,我将通过探索一种新的策略来传递这种放射性核素,从而解决将201Tl具体输送到癌细胞中的挑战,方法是使用与201Tl复合的靶向纹状体蛋白纳米颗粒。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Philip Blower其他文献
The cellular uptake of thallium-201 (201Tl) delivered by Prussian blue nanoparticles is mapped at the subcellular level in lung cancer cells
- DOI:
10.1016/j.bpj.2023.11.2746 - 发表时间:
2024-02-08 - 期刊:
- 影响因子:
- 作者:
Katarzyna Wulfmeier;Juan Pellico;Pedro Machado;Alejandra Carbajal;Saskia Bakker;Philip Blower;Vincenzo Abbate;Samantha Terry - 通讯作者:
Samantha Terry
Philip Blower的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Philip Blower', 18)}}的其他基金
Next generation molecular imaging and therapy with radionuclides
下一代分子成像和放射性核素治疗
- 批准号:
EP/S032789/1 - 财政年份:2019
- 资助金额:
$ 1.23万 - 项目类别:
Research Grant
Radiocopper complexes for imaging & treatment of hypoxic tissues
用于成像的放射性铜配合物
- 批准号:
GR/S60389/02 - 财政年份:2006
- 资助金额:
$ 1.23万 - 项目类别:
Research Grant
相似海外基金
Investigating bioengineering approaches to produce immuno-modulatory mesenchymal stromal cells and their extracellular vesicle
研究生产免疫调节间充质基质细胞及其细胞外囊泡的生物工程方法
- 批准号:
2608627 - 财政年份:2025
- 资助金额:
$ 1.23万 - 项目类别:
Studentship
"Small performances": investigating the typographic punches of John Baskerville (1707-75) through heritage science and practice-based research
“小型表演”:通过遗产科学和基于实践的研究调查约翰·巴斯克维尔(1707-75)的印刷拳头
- 批准号:
AH/X011747/1 - 财政年份:2024
- 资助金额:
$ 1.23万 - 项目类别:
Research Grant
Investigating Dark Matter in Semi-Visible Jets at CERN
欧洲核子研究中心研究半可见喷流中的暗物质
- 批准号:
2907986 - 财政年份:2024
- 资助金额:
$ 1.23万 - 项目类别:
Studentship
Investigating liquid-like mineral phases in crowded media
研究拥挤介质中的液态矿物相
- 批准号:
EP/Y022653/1 - 财政年份:2024
- 资助金额:
$ 1.23万 - 项目类别:
Research Grant
Investigating the acceptability and accuracy of cervical screening and self-sampling in postnatal women to coincide with the 6-week postnatal check-up
调查产后妇女进行宫颈筛查和自我采样以配合产后 6 周检查的可接受性和准确性
- 批准号:
MR/X030776/1 - 财政年份:2024
- 资助金额:
$ 1.23万 - 项目类别:
Research Grant
Investigating the role of complement component 5a in ANCA-associated vasculitis
研究补体成分 5a 在 ANCA 相关血管炎中的作用
- 批准号:
MR/Y000854/1 - 财政年份:2024
- 资助金额:
$ 1.23万 - 项目类别:
Fellowship
Investigating ubiquitination-regulated cell cycle events underpinning malaria transmission
研究泛素化调节的细胞周期事件支撑疟疾传播
- 批准号:
MR/Y013174/1 - 财政年份:2024
- 资助金额:
$ 1.23万 - 项目类别:
Research Grant
Collaborative Research: Investigating Southern Ocean Sea Surface Temperatures and Freshening during the Late Pliocene and Pleistocene along the Antarctic Margin
合作研究:调查上新世晚期和更新世沿南极边缘的南大洋海面温度和新鲜度
- 批准号:
2313120 - 财政年份:2024
- 资助金额:
$ 1.23万 - 项目类别:
Standard Grant
CAREER: Investigating Biogeographic Hypotheses and Drivers of Diversification in Neotropical Harvestmen (Opiliones: Laniatores) Using Ultraconserved Elements
职业:利用超保守元素研究新热带收获者(Opiliones:Laniatores)多样化的生物地理学假设和驱动因素
- 批准号:
2337605 - 财政年份:2024
- 资助金额:
$ 1.23万 - 项目类别:
Continuing Grant
Investigating Multi-Scale Dynamical Processes Amplifying Storm Surges
研究放大风暴潮的多尺度动力学过程
- 批准号:
2342516 - 财政年份:2024
- 资助金额:
$ 1.23万 - 项目类别:
Standard Grant